BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

I Peace partners with the California Institute for Regenerative Medicine

November 3, 2022 | News

Supported by $5.5 billion in funding from the state of California, CIRM has funded 82 clinical trials



Founded in 2015 by Koji Tanabe, a graduate of Professor Shinya Yamanaka's laboratory at Kyoto University in Japan, I Peace, Inc. has partnered with California Institute for Regenerative Medicine's (CIRM) Industry Resource Partner Programme to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programmes funded by CIRM.

I Peace has been providing GMP Induced Pluripotent Stem Cells (iPSC) for a variety of cell therapy developers and pharmaceutical companies with its proprietary technologies for product development in regenerative medicine. CIRM awardees will also have access to I Peace GMP manufacturing services for CIRM Translational and Clinical Stage projects.

Supported by $5.5 billion in funding from the state of California, CIRM has funded 82 clinical trials and is backing more than 152 active regenerative medicine research projects spanning candidate discovery through phase III clinical trials.

The I Peace cell manufacturing facility is certified as cGMP compliant and listed on the FDA "Drug Establishments Current Registration Site". The facility registration, along with DMF registration and GMP certification will open iPSCs market for clinical and commercial purposes in the United States, Japan, and other global markets.